Subgroup results from KARDIA-2: impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive

医学 内科学 子群分析 基线(sea) 疾病 心脏病学 置信区间 地质学 海洋学
作者
Manjari Saxena,Ahmad Aswad,Jolita Badarienė,Faiz Karim,Ying Tung Sia,Daniel Stiglitz,Nune Makarova,Andrei Havași,D Zappe,George L. Bakris
出处
期刊:European Heart Journal [Oxford University Press]
卷期号:45 (Supplement_1) 被引量:2
标识
DOI:10.1093/eurheartj/ehae666.2593
摘要

Abstract Background Zilebesiran is an investigational RNA interference therapeutic targeting hepatic angiotensinogen synthesis. In KARDIA-1, a single subcutaneous (SC) dose of zilebesiran monotherapy significantly reduced 24-hr mean ambulatory and office systolic blood pressure (SBP) from baseline to Months 3 and 6 versus placebo. The Phase 2 KARDIA-2 study assessed efficacy and safety of zilebesiran with a standard oral antihypertensive in patients with uncontrolled hypertension. Purpose Uncontrolled hypertension is a leading cause of cardiovascular morbidity and mortality, and medication non-adherence affects blood pressure control. Developing effective, long-lasting treatments is crucial for patients with hypertension uncontrolled by standard therapy. Methods KARDIA-2 enrolled adults with mild-to-moderate hypertension who were untreated or receiving stable therapy with ≤2 antihypertensives. Patients discontinued prior antihypertensive medication and were randomized 10:7:4 to open-label, once-daily oral treatment with 40 mg olmesartan, 5 mg amlodipine, or 2.5 mg indapamide. After ≥4 weeks on protocol-specified medication, patients with a 24-hr mean ambulatory SBP of 130–160 mmHg were randomized 1:1 in a double-blind manner to a single SC dose of zilebesiran 600 mg or placebo as add-on therapy. The primary endpoint was change from baseline to Month 3 in 24-hr mean ambulatory SBP versus placebo for each group. Efficacy and safety were also assessed in pre-specified subgroups: age (<65; ≥65 years), sex, race (Black; other), baseline 24-hr mean ambulatory SBP (<145; ≥145 mmHg), and baseline estimated glomerular filtration rate (≥60; <60 mL/min/1.73m2). Results The primary analysis included 667 patients (median age [range] 59 [27–75] years; 57% male, 28% Black). At Month 3, least-squares mean differences (LSMD) (95% confidence interval [CI]) between zilebesiran and placebo for the olmesartan, amlodipine, and indapamide groups were −4.0 (−7.6, −0.3), −9.7 (−12.9, −6.6), and −12.1 (−16.5, −7.6) mmHg, respectively, for 24-hr mean ambulatory SBP (all p<0.05). LSMD (95% CI) in office SBP for the same groups were −7.0 (−10.4, −3.6), −10.2 (−13.5, −6.9), and −18.5 (−22.8, −14.2) mmHg, respectively, (all p<0.001). SBP reductions were consistent across subgroups, except for a trend towards an attenuated response observed in Black patients (Figs 1, 2). More patients receiving zilebesiran (49–58%) than placebo (39–48%) experienced ≥1 adverse event through Month 6, with low rates of hyperkalaemia, hypotension, or acute kidney injury reported across all groups. Conclusion In KARDIA-2, a single dose of zilebesiran significantly reduced SBP versus placebo at Month 3 on top of a standard oral antihypertensive, with encouraging safety data. SBP reduction was consistent across most subgroups. Treatment with zilebesiran combined with standard antihypertensives may be effective for a broad population of patients with hypertension uncontrolled on monotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
充电宝的应助被wangfei采纳,获得10
刚刚
alan发布了新的文献求助30
1秒前
1秒前
踏实煎蛋发布了新的文献求助10
2秒前
3秒前
Grey完成签到,获得积分10
3秒前
3秒前
qq发布了新的文献求助10
4秒前
我有我风格完成签到 ,获得积分10
5秒前
久伴发布了新的文献求助10
6秒前
完美世界的应助被一颗两颗星采纳,获得10
6秒前
FashionBoy的应助被sss采纳,获得10
6秒前
hbutsj发布了新的文献求助10
7秒前
8秒前
丘比特的应助被FaFa采纳,获得10
8秒前
9秒前
10秒前
扶摇完成签到,获得积分10
10秒前
303完成签到 ,获得积分10
11秒前
12秒前
xx发布了新的文献求助10
13秒前
FaFa完成签到,获得积分10
13秒前
爆米花的应助被lilac采纳,获得10
13秒前
li完成签到 ,获得积分10
15秒前
11完成签到,获得积分10
15秒前
wangfei发布了新的文献求助10
15秒前
smy完成签到 ,获得积分10
15秒前
温暖的夏蓉完成签到 ,获得积分10
16秒前
16秒前
heee完成签到 ,获得积分10
17秒前
FashionBoy的应助被hml123采纳,获得10
17秒前
xxy完成签到,获得积分10
17秒前
qq完成签到,获得积分20
18秒前
18秒前
Lily发布了新的文献求助10
18秒前
123发布了新的文献求助10
18秒前
18秒前
芋头完成签到 ,获得积分20
19秒前
科研通AI6.3的应助被yyyhan采纳,获得10
19秒前
shell完成签到 ,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188221
求助须知:如何正确求助?哪些是违规求助? 9576025
关于积分的说明 21845049
捐赠科研通 7786165
什么是DOI,文献DOI怎么找? 3435226
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482157